Phase 3 study of lasmiditan for acute treatment of migraine

Lasmiditan is a selective 5-HT1F receptor agonist without vasoconstrictive activity. In this phase 3 double-blind placebo-controlled study, Goadsby et al. show that lasmiditan is efficacious and relatively well tolerated in the acute treatment of migraine in adults, including those with cardiovascular risk factors or a prior history of cardiovascular events.